{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T20:55:39Z","timestamp":1770152139897,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.7759\/cureus.98837","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:49:36Z","timestamp":1765320576000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Symptomatic Bradycardia Following First-Dose Oxcarbazepine in a Very Elderly Patient on Long-Term Carbamazepine: A Case Report"],"prefix":"10.7759","author":[{"given":"Yixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00523-z","article-title":"Trigeminal neuralgia","volume":"10","author":"Ashina S","year":"2024","unstructured":"Ashina S, Robertson CE, Srikiatkhachorn A, et al.. Trigeminal neuralgia. Nat Rev Dis Primers. 2024, 10:39. 10.1038\/s41572-024-00523-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007963.pub3","article-title":"Oxcarbazepine for neuropathic pain","volume":"12","author":"Zhou M","year":"2017","unstructured":"Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2017, 12:CD007963. 10.1002\/14651858.CD007963.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.07.004","article-title":"What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?","volume":"5","author":"Schmidt D","year":"2004","unstructured":"Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?. Epilepsy Behav. 2004, 5:627-35. 10.1016\/j.yebeh.2004.07.004","journal-title":"Epilepsy Behav"},{"key":"ref4","article-title":"Oxcarbazepine","author":"Preuss CV","year":"2025","unstructured":"Preuss CV, Randhawa G, Saadabadi A. Oxcarbazepine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-017-0441-0","article-title":"Sodium channel blockers in the treatment of epilepsy","volume":"31","author":"Brodie MJ","year":"2017","unstructured":"Brodie MJ. Sodium channel blockers in the treatment of epilepsy. CNS Drugs. 2017, 31:527-34. 10.1007\/s40263-017-0441-0","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210302","article-title":"Cardiac conduction delay for sodium channel antagonist antiseizure medications: an analysis of the Canadian Longitudinal Study on Aging","volume":"104","author":"Shlobin NA","year":"2025","unstructured":"Shlobin NA, Li J, Sander JW, Keezer MR, Thijs RD. Cardiac conduction delay for sodium channel antagonist antiseizure medications: an analysis of the Canadian Longitudinal Study on Aging. Neurology. 2025, 104:e210302. 10.1212\/WNL.0000000000210302","journal-title":"Neurology"},{"key":"ref7","unstructured":"TRILEPTAL (oxcarbazepine) approval labeling. (2014). Accessed. November 11, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/21014lbl.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2020.61.10.875","article-title":"Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital","volume":"61","author":"Lee JE","year":"2020","unstructured":"Lee JE, Min KR, Kim SH, Kim AH, Kim ST. Analysis of adverse drug reactions with carbamazepine and oxcarbazepine at a tertiary care hospital. Yonsei Med J. 2020, 61:875-9. 10.3349\/ymj.2020.61.10.875","journal-title":"Yonsei Med J"},{"key":"ref10","article-title":"One case of sinus bradycardia induced by oxcarbazepine (Article in Chinese)","volume":"36","author":"Zhao Q","year":"2019","unstructured":"Zhao Q, Li X, Feng P, Zhu J, Liang B. One case of sinus bradycardia induced by oxcarbazepine (Article in Chinese). Chinese J Mod Appl Pharm. 2019, 36:225-6.","journal-title":"Chinese J Mod Appl Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00540-y","article-title":"Heart failure with preserved ejection fraction","volume":"10","author":"Hamo CE","year":"2024","unstructured":"Hamo CE, DeJong C, Hartshorne-Evans N, Lund LH, Shah SJ, Solomon S, Lam CS. Heart failure with preserved ejection fraction. Nat Rev Dis Primers. 2024, 10:55. 10.1038\/s41572-024-00540-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01067-1","article-title":"Pathophysiological insights into HFpEF from studies of human cardiac tissue","volume":"22","author":"Fayyaz AU","year":"2025","unstructured":"Fayyaz AU, Eltony M, Prokop LJ, et al.. Pathophysiological insights into HFpEF from studies of human cardiac tissue. Nat Rev Cardiol. 2025, 22:90-104. 10.1038\/s41569-024-01067-1","journal-title":"Nat Rev Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-305664","article-title":"Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications","volume":"101","author":"Bardai A","year":"2015","unstructured":"Bardai A, Blom MT, van Noord C, Verhamme KM, Sturkenboom MC, Tan HL. Sudden cardiac death is associated both with epilepsy and with use of antiepileptic medications. Heart. 2015, 101:17-22. 10.1136\/heartjnl-2014-305664","journal-title":"Heart"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills GJ","year":"2020","unstructured":"Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020, 168:107966. 10.1016\/j.neuropharm.2020.107966","journal-title":"Neuropharmacology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2021.1254","article-title":"Identifying patients with epilepsy at high risk of cardiac death: signs, risk factors and initial management of high risk of cardiac death","volume":"23","author":"Surges R","year":"2021","unstructured":"Surges R, Shmuely S, Dietze C, Ryvlin P, Thijs RD. Identifying patients with epilepsy at high risk of cardiac death: signs, risk factors and initial management of high risk of cardiac death. Epileptic Disord. 2021, 23:17-39. 10.1684\/epd.2021.1254","journal-title":"Epileptic Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.159","article-title":"The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose","volume":"46","author":"Boyd RA","year":"1989","unstructured":"Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, Giacomini KM. The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther. 1989, 46:408-19. 10.1038\/clpt.1989.159","journal-title":"Clin Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.paf.0000257399.58935.28","article-title":"Verapamil toxicity: an unusual case report and review of the literature","volume":"28","author":"Batalis NI","year":"2007","unstructured":"Batalis NI, Harley RA, Schandl CA. Verapamil toxicity: an unusual case report and review of the literature. Am J Forensic Med Pathol. 2007, 28:137-40. 10.1097\/01.paf.0000257399.58935.28","journal-title":"Am J Forensic Med Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-003-1658-3","article-title":"How is oxcarbazepine different from carbamazepine? (Article in German)","volume":"75","author":"Schmidt D","year":"2004","unstructured":"Schmidt D, Elger CE. How is oxcarbazepine different from carbamazepine? (Article in German). Nervenarzt. 2004, 75:153-60. 10.1007\/s00115-003-1658-3","journal-title":"Nervenarzt"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209177","article-title":"Sudden cardiac death or ventricular arrythmia in patients taking levetiracetam or oxcarbazepine","volume":"102","author":"Cross MR","year":"2024","unstructured":"Cross MR, Savitz ST, Sangaralingham LR, So EL, Ackerman MJ, Noseworthy PA. Sudden cardiac death or ventricular arrythmia in patients taking levetiracetam or oxcarbazepine. Neurology. 2024, 102:e209177. 10.1212\/WNL.0000000000209177","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1535759721996344","article-title":"FDA safety warning on the cardiac effects of lamotrigine: an advisory from the ad hoc ILAE\/AES task force","volume":"21","author":"French JA","year":"2021","unstructured":"French JA, Perucca E, Sander JW, et al.. FDA safety warning on the cardiac effects of lamotrigine: an advisory from the ad hoc ILAE\/AES task force. Epilepsy Curr. 2021, 21:150-3. 10.1177\/1535759721996344","journal-title":"Epilepsy Curr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444520-severe-symptomatic-bradycardia-following-first-dose-oxcarbazepine-in-a-very-elderly-patient-on-long-term-carbamazepine-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T22:49:36Z","timestamp":1765320576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444520-severe-symptomatic-bradycardia-following-first-dose-oxcarbazepine-in-a-very-elderly-patient-on-long-term-carbamazepine-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.98837","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}